Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Becker's muscular dystrophy Stories

2009-10-16 10:26:00

DALLAS, Oct. 16 /PRNewswire-USNewswire/ -- John Killian, Chairman of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), and his wife Stefanie Killian, announced today that the 5th Annual Sam's Family Fun Day (Sam's Day) will take place on October 24, 2009 from 10am to 2pm on Flagpole Hill at White Rock Lake. (Photo: http://www.newscom.com/cgi-bin/prnh/20091016/DC93763)...

2009-10-13 00:00:00

AMSTERDAM, October 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy. Orphan Drug Designation for Duchenne muscular dystrophy (DMD) entitles AMT to ten year market exclusivity in Europe following marketing approval for AMT-080 if this...

2009-09-29 06:00:00

Duchenne Organization Competes With Over 500 Nonprofits To Win Grand Prize MIDDLETOWN, Ohio, Sept. 29 /PRNewswire-USNewswire/ -- Intel, as Sponsors of Tomorrow(TM), announced Parent Project Muscular Dystrophy (PPMD) as the winner of its Vote For A Cause contest on its Facebook Page. Over 600 nonprofit organizations were nominated and based upon online voting by Facebook members, organizations were eliminated through five rounds of competition. PPMD is the recipient of $50,000 in...

2009-06-24 08:04:41

A group led by Dr. Paul T. Martin of The Ohio State University College of Medicine has demonstrated that the glycosyltransferase Galgt2 can lessen symptoms in multiple models of muscular dystrophy. Their report can be found in the July 2009 issue of the American Journal of Pathology.Muscular dystrophy is a group of inherited muscular disorders that are characterized by progressive skeletal muscle weakness, defects in muscle proteins, and the death of muscle cells and tissue. Recent studies...

2009-06-22 13:51:00

Senator Johnny Isakson, American Football Coaches Association to Receive Awards MIDDLETOWN, Ohio, June 22 /PRNewswire-USNewswire/ -- Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced that PPMD will be honoring United States Senator Johnny Isakson and the American Football Coaches Association (AFCA) with...

2009-06-18 12:36:10

British medical scientists say they used an animal study to demonstrate a method of making an early diagnosis of muscular dystrophy, before symptoms develop. University of Birmingham researchers said they used mice to study the key proteins involved in two types of muscular dystrophy -- Duchenne muscular dystrophy and a milder form, Limb Girdle MD. The researchers said they identified disrupted stem cell function and delays of skeletal muscle formation in embryos of muscular dystrophy-like...

2009-06-18 07:09:07

The saying "knowing is half the battle" is never more powerful than in early diagnosis and treatment of disease. Muscular dystrophy is one such disease where patients can benefit from early treatment. Researchers at the School of Biosciences, University of Birmingham, United Kingdom, used mice as models to study the key proteins involved in two types of muscular dystrophy (MD): the most severe MD form, Duchenne Muscular Dystrophy (DMD), and a milder form, Limb Girdle MD. The researchers found...

2009-06-17 09:59:13

The saying "Knowing is half the battle" is never more true than when discussing early treatment of disease. Muscular dystrophy is one such disease where patients can benefit from early treatment. Now, new research is moving doctors and scientists closer to disease diagnosis in advance of patient symptoms.A team of University of Birmingham researchers used mice as model animals to study the key proteins involved in two types of muscular dystrophy (MD): the most severe MD form, Duchenne...

2009-06-15 07:00:00

- Funding supports continued focus on rare disorders - SOUTH PLAINFIELD, N.J., June 15 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of two government grants to support clinical development programs in rare disorders. The U.S. Department of Defense Neurofibromatosis Research Program has awarded an $822,345 grant to support a new open-label Phase 2 clinical trial of PTC's product candidate PTC299 in neurofibromatosis type 2 (NF2), a rare genetic tumor. Separately,...

2009-05-27 16:09:19

U.S. medical scientists say they've developed a new therapy for Duchenne musclar dystrophy, a fatal disease and the most common form of MD in children. Researchers at the University of Minnesota Medical School, using a mouse model, said they were able to substitute for the missing protein dystrophin, which forms a key part of the framework that holds muscle tissue together. The scientists injected dystrophic mice with a protein called utrophin -- a close relative of dystrophin -- that was...